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Objectives
After completion of this program, the reader should be able to:
1. State the NCCN goals of palliative care.
2. Identify appropriate pharmacologic palliative care.
3. List several scientifically validated nonpharmacologic options of palliative care.
4. Assess clinical studies to implement effective palliative care options for patients.
Abstract
In recent decades, few fields have changed as drastically as
oncology. A wide variety of approaches must be taken in order to best care for cancer patients. With the globalization of
health care and modern society, nontraditional management
of cancer symptoms is once again increasing in popularity.
The National Comprehensive Cancer Network (NCCN) has
also recently updated their palliative care guidelines. These
guidelines provide a detailed approach for the care of a wide
range of cancer patients but largely focus on traditional pharmacotherapy. An increasing number of studies are being conducted on nonpharmacologic approaches to care for patients
with cancer. These strategies range from mindfulness-based
stress reduction (MBSR) and acupuncture to massage and
music therapy. As easily accessible and highly trusted health
care professionals, pharmacists have a duty to know not only
about appropriate pharmacologic palliative care but also
appropriate nonpharmacologic alternatives to recommend to
patients and providers.
Key Terms
Alternative Medicine; Medicine; Complimentary; Oncology;
Medical; Palliative Care; Pharmacists
Introduction
In recent decades, few fields have changed as drastically as
oncology. However, with more numerous and effective treatment options, new challenges have appeared. In general, patients with cancer are living longer today than in years past.
Although many are surviving with few additional needs,
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many patients still require care for advanced or terminal
disease. Furthermore, the health care community has
realized that each cancer patient responds differently to
treatment. Therefore, a wide variety of approaches must be
taken in order to best care for this population. With the globalization of health care and modern society, nontraditional
management of cancer symptoms is once again increasing in
popularity. This article will explore the most recent guidelines for pharmacologic palliative care as well as specific
studies addressing nonpharmacologic options that patients
and providers may encounter.
Practice Guidelines
Palliative care is an integral part of cancer therapy. The goals
of palliative care should be to "anticipate, prevent, and reduce suffering and to support the best possible quality of life
for patients and their families," according to the National
Comprehensive Cancer Network (NCCN) Palliative Care
Guidelines. 1 Palliative care should be initiated at diagnosis
and continued throughout treatment relative to the needs of
the patient, whether treatment is curative or simply prolonging life. For the best patient outcomes, an interdisciplinary
team consisting of board certified palliative care physicians,
advanced practice nurses, physician assistants, pharmacists,
social workers and chaplains should be utilized.
After diagnosis, every patient should be screened by their
providers at each visit for the following: unmanaged symptoms, emotional distress due to therapy and diagnosis,
comorbid conditions, decreasing life expectancy, metastatic
tumors, or patient and/ or family requests for palliative care.1
Patients should be continuously reevaluated at each subsequent visit, and palliative therapy should be adjusted as necessary according to the needs of the patient.
The goals of anticancer therapy should be set in relation to
the estimated life expectancy of the patient, which will then
help determine the best approach to palliative care.1 Anticancer therapy can be both physically and mentally taxing on
the patient and family. The benefits and burdens of therapy
must be properly communicated ensuring that the most effective course of therapy is selected according to the wishes
of the patient. If it is determined that a patient has months to
years in life expectancy, the patient should be made aware if
treatment is palliative or curative and of the anticipated burdens associated with the selected therapy. Once the goals of
the therapy are stated, the patient can begin to psychologically prepare for the disease progression and treatment
regimen, an aspect unique to palliative care providers. If a
patient has months to weeks or weeks to days, ensure the
patient is aware of the incurability of their disease. Establish-

THE PHARMACY AND WELLNESS REVIEW

9

Oncology

Pharmacologic and Nonpharmacologic Approaches to Palliative Care in Oncology

ing updated goals as the disease progresses can help transition into providing extensive symptom relief during the
dying process. This can include discontinuing inherently
aggressive anticancer therapies and focusing on palliating
physical and psychological symptoms to increase quality of
life and comfort for the dying patient.
ln cancer and cancer therapy, there is an overarching
symptomatology associated with treatment and disease
progression. 1 Pain, dyspnea and fatigue are among the more
prevalent symptoms along with gastrointestinal complications such as constipation, diarrhea, and nausea and vomiting, which can exacerbate anorexia or cachexia.
Pain: Controlling pain in cancer is essential to maximizing patient outcomes and quality of life. Patients with longer
life expectancies will follow the NCCN Cancer Pain Management guidelines while end stage patients will additionally
follow the palliative care guidelines.1 The Cancer Pain Management Guidelines suggest titrating short acting opioids in
both opioid naive and tolerant patients either orally or intravenously using morphine or morphine equivalents.2 Titration
should be to the patient's acceptable pain intensity and
opioid tolerability. If the patient's pain is not adequately
controlled, an increase of 50 to 100 percent of the opioid
dose is indicated at the discretion of the provider. As the
disease progresses or remits, it is imperative to constantly
reassess pain intensity and goals in order to avoid supratherapeutic or subtherapeutic levels.
In patients with reduced life expectancies, the recommendations suggest a more aggressive approach to titration.1· 3
Doses should not be reduced for decreasing blood pressure,
respiratory rate or consciousness as long as pain is being
managed to the patient's preference. This aggressive approach can increase the risk of neurotoxicities such as myoclonus and hyperalgesia, so managing the symptoms with
appropriate opioid rotation and rehydration is imperative
for increased quality of life.1 In general, opioid dose reduction should be avoided to prevent acute withdrawal symptoms or reemergence of pain. If necessary, cautiously reduce
opioid dose by 25 to 50 percent every 24 hours, while avoiding the use of opioid antagonists. Disease progression can
also require changing routes of administration from oral to
various different routes using the appropriate dosing conversions found in the corresponding package inserts.4
Dyspnea: Dyspnea is a common symptom in cancer because it is multifactorial and usually secondary to other
symptoms.1 Lung cancer contributes considerably to the
presence of dyspnea among all cancer patients. The intensity
of discomfort during breathing should be assessed and
underlying conditions or comorbidities should be treated
according to life expectancy. For patients with longer life
expectancies, interventional options include radiation and
chemotherapy, removal of cardiac, pleural or abdominal fluids or bronchoscopic therapies.s Continuous positive airway
pressure and bi-level positive airway pressure can be used if
the condition is reversible. 1 Pharmacologic treatments of
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underlying conditions are also an option, which include the
utilization of bronchodilators, diuretics, steroids, antibiotics,
transfusions or anticoagulants if a pulmonary embolism develops. Morphine also has dual utilization as it can reduce
dyspnea in the opioid naive if dosed around the clock. If morphine is ineffective and dyspnea is rooted in anxiety associated with cancer, benzodiazepines are indicated but are not
shown to reduce dyspnea unless anxiety-induced.6 Therapy
for patients with a reduced life expectancy is less invasive
with a focus on symptom alleviation.1 There are similarities
in pharmacologic interventions such as morphine in the opioid naive, benzodiazepines if anxiety-induced, and diuretics.
Additional options include a decrease in enteral or parenteral fluids to decrease fluid retention, a 25 percent increase in
chronic opioid dose, or the use of anticholinergic agents to
decrease excessive secretions. The preferred agents are
scopolamine (subcutaneous or transdermal), ophthalmic
atropine (sublingual) or glycopyrrolate (intravenous or subcutaneous). One of the last options when the disease is in its
final stages, is a time-limited trial of mechanical ventilation,
dependent upon the preference of the patient and family.
Cachexia or Weight Loss: Another series of symptoms in
cancer patients is the physical deterioration of skeletal and
muscle mass, known as cachexia. The development of anorexia, or the lost desire to eat, further exacerbates the cachectic state of the patient.1 To help prevent cachexia and
anorexia, recognizing inducible factors such as distorted
tastes, or dysgeusia, xerostomia, mucositis, gastroparesis,
nausea and vomiting, constipation, pain, fatigue and a psychological distortion of one's self appearance is key to improving patient outcomes. Also, providers must determine if
there are comorbidities present in the patient that might be
causing the anorexia or cachexia and treat these conditions
appropriately. This could include hypogonadism, thyroid
dysfunction or other metabolic anomalies. There are both
pharmacologic and nonpharmacologic treatments available
to help prevent anorexia and cachexia, but the following
pharmacologic strategies can be employed to help treat underlying conditions and contributing factors. If an oral or
pharyngeal candidiasis infection is contributing to the lost
desire to eat, treat the infection appropriately with either
oral or topical solutions. Sometimes, anorexia is attributable
to depression associated with the cancer diagnosis or prognosis or a preexisting anorexic diagnosis. Mirtazapine can be
prescribed to treat this depression and has the added benefit
of stimulating appetite. Other appetite stimulants are also
recommended for patients with a decreased life expectancy.
These include megestrol acetate, olanzapine, dexamethasone
and cannabinoids.7 As the patients reach the end of life, providers must educate both patients and family members about
the inevitable symptoms and decisions they will face.1 In the
dying patient, anorexia and lack of thirst are quite common
and should be palliated by proper mouth care and frequent,
small amounts of fluids. Also, the patient may experience a
complete metabolic shutdown even if they are given total parenteral nutrition (TPN). Withholding TPN from the dying patient is
ethically sound and could prevent additional complications such
as infection and refeeding syndrome.1,s
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Nausea and Vomiting: Nausea and vomiting are symptoms that present in many cancer patients receiving chemotherapeutic agents.1 Special care must be taken to properly
premedicate these patients. First, check therapeutic levels of
other agents known to induce nausea and vomiting such as
phenytoin, digoxin, carbamazepine and tricyclic antidepressants. Determine if it is feasible to decrease the current dose,
find a therapeutic equivalent or discontinue the medication.
Nausea and vomiting are also nonspecific symptoms associated with other disease states. Providers must diagnose and
treat the following possible underlying conditions: gastroparesis, central nervous system involvement, gastritis/
gastroesophageal reflux and correcting metabolic abnormalities such as hypercalcemia, uremia or dehydration. Rotating
or reducing chronic opioids and substituting them with coanalgesics without emetic or nauseating side effects can also
reduce symptoms. If the cancer itself is the direct precipitating factor, consider palliative radiation, dexamethasone, proton pump inhibitors (PPis), metoclopramide, endoscope
stenting or a G-tube. For patients who have persistent nausea
and vomiting, titrate dopamine receptor antagonists
(prochlorperazine, haloperidol, metoclopramide, olanzapine)
to the patient's tolerability. If symptoms still persist, consider
adding one or more of the following agents: S-HT3 receptor
antagonists (ondansetron), anticholinergics (scopolamine),
antihistamines (meclizine) or cannabinoids. For refractory
patients, add dexamethasone or olanzapine if the patient is
not already receiving these medications. Patients might also
experience psychological disorders that contribute to nausea
and vomiting. If so, consider adding a dopamine receptor
antagonist, lorazepam or a cannabinoid.
Constipation: Because of the heavy reliance on opioids
for cancer pain management, opioid induced constipation is
expected to be a symptom experienced almost universally
among cancer patients.1 Comorbidities such as hypothyroidism, diabetes mellitus, hypokalemia and hypercalcemia can
also contribute to constipation; so providers must treat these
conditions as well. In the treatment of constipation, simple
lifestyle or dietary modifications can help, but pharmacologic
agents are often necessary to produce bowel movements.
Traditional agents such as sennosides and docusate can be
titrated to maximum doses at intervals of two to three times
a day to produce one bowel movement every one to two
days. Bisacodyl up to three times a day may be added if the
patient still cannot produce a bowel movement. For patients
refractory to the above treatments, providers can add bisacodyl suppositories, polyethylene glycol, lactulose, sorbitol or
magnesium-based solutions. Tap water enemas and metoclopramide are suggested if the patient remains refractory, but
only as last line options. There are numerous medications that
can induce constipation; so providers should consider the benefits of discontinuing nonessential agents that are known to
constipate patients. If the patient is fecally impacted, utilize a
glycerin suppository and/ or a mineral oil. If necessary, manually disimpact after premedicating the patient with analgesics
and anxiolytics. Newer agents specifically targeted to treat opioid induced constipation, like methylnaltrexone, can be injected subcutaneously to help produce bowel movements.
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Diarrhea: There are many causes that can contribute to
diarrhea such as infection, antibiotics, anticancer treatment,
impaction or changes in diet and exercise.1 Severity and
grading of diarrhea is based upon the number of stools per
day over the patient's baseline. Grade 1 is less than four
stools per day, grade 2 is between four and six stools per day,
grade 3 is over seven stools per day requiring hospitalization
and grade 4 is an urgent, life-threatening emergency situation. Grade 1 patients are initially treated with oral rehydration and electrolyte supplementation. Antidiarrheals such as
loperamide or diphenoxylate-atropine are also recommended. Patients can adhere to the BRAT diet: bananas, rice, applesauce and toast. If the chemotherapy regimen is causing
diarrhea, the chemotherapy dose can be reduced or withheld, although neither option is ideal. Grade 2 patients are
continued on antidiarrheals, but intravenous (IV) fluids are
initiated if the patient is unable to tolerate oral hydration.
Anticholinergics such as hyoscyamine and atropine can also
be added in conjunction with antidiarrheals. Infections such
as Clostridium difficile can occur in cancer patients due to
chemotherapy and nosocomial acquisitions. Treat moderate
C. difficile with oral metronidazole and severe C. difficile with
oral vancomycin for 10 to 14 days.4 Patients receiving ipilimumab for metastatic melanoma can also experience grade 2
diarrhea, so it is recommended to consider either infliximab
or corticosteroids as alternative therapy.1 Grades 2 through 4
also follow the above guidelines, with the addition of octreotide. However, recommendations are different for patients near death. These patients have the option of home
infusion for IV rehydration, initiation of around the clock
opioids or dose increase to induce constipation, octreotide or
glycopyrrolate to help maximize comfort level in the final
days of life.
Sleep Disturbances: Cancer patients often experience
disturbances in sleep leading to insomnia and daytime
drowsiness.1 Severity of the disturbances should be assessed
using metrics such as the Epworth Sleepiness scale. After
determining the severity of the disturbances, prescribers
should attempt to determine the causative factors behind
them. Anxiety and fears about the disease, as well as contemplation of death, often weigh heavily in these disturbances.
Providers should counsel their patients on proper sleep hygiene or refer them for cognitive behavioral therapy for
treatment of depression and/or anxiety.
Medication withdrawal or side effects sometimes lead to disturbances. Corticosteroids, opioids, anticonvulsants, caffeine,
hormones, herbals, barbiturates, benzodiazepines, alcohol
and tricyclic antidepressants are all offending agents. Proper
management and tapering should be performed to reduce
discomfort. Underlying conditions such as obstructive sleep
apnea or restless leg syndrome also prevent sleep for cancer
patients. Proper continuous positive or bi-level airway pressure therapy should be used for sleep apnea, while ropinirole, pramipexole with pregabalin, and carbidopa-levodopa
are options for restless leg syndrome. If the patient is still
experiencing disturbances leading to insomnia, medications
that induce somnolence can be prescribed. These include:
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Table 1. Summary of Pharmacologic Interventions for Symptoms Associated with Cancer Treatment.1-s
Proposed Therapy

Indication

Longer life expectancy
Short acting opioids, titrated up to 50-100% at the discretion of the provider
-Years, years to months, months to weeks
Pain

Dyspnea

Reduced life expectancy
-Weeks to days

More aggressive dosing and titration, doses should not be reduced for decreasing
blood pressure, respiratory rate or consciousness as long as pain is being managed to the patient's preference, avoid opioid dose reduction, reduce opioid dose
by 25-50% every 24 hours if necessary, avoid opioid antagonists

Radiation and chemotherapy, removal of cardiac, pleural, or abdominal fluids,
bronchoscopic therapies, continuous positive airway pressure (CPAP) or bi-level
Longer life expectancy
-Years, years to months, months to weeks positive airway pressure (BiPAP) therapy if condition is reversible, morphine in
opioid na'ive, benzodiazepine if anxiety-induced
Reduced life expectancy
-Weeks to days

Morphine in opioid na'ive, benzodiazepine if anxiety-induced, scopolamine (subQ
or transdermal), ophthalmic atropine (sublingual), glycopyrrolate (subQ or IV),
time-limited mechanical ventilation as one of the last options

Presence of oral or pharyngeal candidiasis infection

Oral or topical antifungal regimens

Cachexia or Depression associated with cancer diagWeight Loss nosis/ prognosis or preexisting anorexia Mirtazapine
diagnosis

Nausea or
Vomiting

Constipation

Patients with decreased life expectancy

Megestrol acetate, olanzapine, dexamethasone, cannabinoids

Cancer as precipitating factor

Palliative radiation, dexamethasone, PPls, metoclopramide, endoscopic stenting,
G-tube

Persistent nausea and vomiting

Prochlorperazine, haloperidol, metoclopramide, olanzapine titrated to patient's
tolerability

Ineffective treatment of persistent nausea and vomiting

Addition of ondansetron, scopolamine, meclizine or cannabinoids

Refractory patients

Addition of dexamethasone or olanzapine unless already included in treatment

Psychological disorders contributing to
nausea and vomiting

Addition of dopamine receptor antagonist, lorazepam or cannabinoid

First-line treatment

Sennosides and docusate titrated to maximum doses 2-3 times per day

Patient unable to produce bowel movement after initial treatment

Bisacodyl up to 3 times per day

Refractory patients

Bisacodyl suppositories, polyethylene glycol, lactulose, sorbitol or magnesiumbased solutions

Refractory patients if above therapies fail Tap water enemas, metoclopramide

Diarrhea

Fecal impaction

Glycerin suppository and/or mineral oil

Grade 1 diarrhea

Oral rehydration and electrolyte supplementation, loperamide, diphenoxylateatropine

Grade 2 diarrhea

Antidiarrheals continued, addition of hyoscyamine or atropine

Grade 2 diarrhea in patient unable to
tolerate oral hydration

Initiation of!V fluids

Grade 2 diarrhea in patients receiving
ipilimumab for metastatic melanoma

Consider infliximab or corticosteroids as alternative therapy

Grade 2-4 diarrhea

Addition of octreotide

Grade 2-4 diarrhea in patients near death

Home infusion for IV rehydration, around the clock opioids or dose increase, octreotide, or glycopyrrolate

Clostridium difficile due to chemotherapy
Metronidazole (oral) if moderate, vancomycin (oral) x 10-14 days if severe
or nosocomial acquisition
Sleep apnea

CPAP/BiPAP therapy

Restless leg syndrome

Ropinirole, pramipexole with pregabalin, carbidopa-levodopa

Sleep
Continued sleep disturbances after initial Trazodone, olanzapine, zolpidem, mirtazapine, chlorpromazine, quetiapine, loDisturbances therapy
razepam

12

Daytime fatigue

Caffeine, methylphenidate, dextroamphetamine, modafinil

End oflife patient

Chlorpromazine if required
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trazodone, olanzapine, zolpidem, mirtazapine, chlorpromazine, quetiapine or lorazepam. Daytime fatigue may be treated with caffeine, methylphenidate, dextroamphetamine and
modafinil. Finally, in the dying patient, sedation level should
be determined according to the patient's wishes and the
wishes of the family. If required, chlorpromazine can be initiated at bedtime for insomnia.

Nonpharmacologic Intervention
Nonpharmacologic interventions are important to consider
as treatment options or adjuncts to traditional pharmacologic treatments for cancer patients. Sometimes pharmacologic
treatments may not be sufficient alone or patients may want
more natural options. Thus, it is important that pharmacists
understand the nonpharmacologic treatment options that
are available to patients attempting to manage their chronic
pain. There are a variety of interventions that are being studied or have yet to be studied in cancer patients who are
thought to have at least some potential to decrease pain and
improve quality of life.
Massage therapy is becoming more frequently used in cancer
patients to help relieve symptoms.9 Massage involves the
manipulation of soft tissue areas of the body and has traditionally been used in multiple clinical settings to help patients sleep more easily, relax and to help relieve aches and
pains in the muscles. The NCCN recommends that massage
therapy be included in the treatment guidelines for refractory cancer pain.2 Several studies have been conducted that
suggest massage therapy can be used to reduce pain for cancer patients in a variety of stages.10
A large study conducted at Memorial Sloan-Kettering Cancer
Center over a three-year period included 1,290 patients.9 The
patients reported how severe their symptoms were premassage therapy and postmassage therapy using 0 to 10 rating
scales for symptoms including pain, fatigue, stress/anxiety,
nausea and depression. After therapy, symptom scores decreased by nearly SO percent. Three types of massage therapy were available including the standard Swedish massage,
light touch massage and foot massage in order to determine
if a specific type of massage provided superior benefits. The
therapy sessions were about 20 minutes for inpatients and
60 minutes for outpatients. Before and after the session, the
patients were given a card with each symptom and were instructed to rate the symptom on a scale from 0 to 10, with 0
being not at all bothersome and 10 being extremely
bothersome. Overall, out of 1,131 patients, the average
combined overall symptom baseline score was 7.3 and
posttreatment was 3.5 leading to a 52 percent improvement
after massage therapy. The following are the results for each
of the symptoms specifically after massage therapy: pain,
n=625, baseline=6.1, posttreatment=3.3, improvement=47.8
percent; fatigue, n=819, baseline=6.6, posttreatment=3.8,
improvement=42.9 percent; anxiety, n=786, baseline=6.7,
posttreatment=2.7, improvement=59.9 percent; nausea,
n=222, baseline=6, posttreatment=3, improvement=Sl.4
percent; depression, n=378, baseline=6.2, posttreatment=3.2,
improvement=48.9 percent. Table 2 provides a summary of
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the results for each of the symptoms after massage therapy.
Differences in effect from baseline to posttreatment by type
of massage therapy were also analyzed: Swedish massage,
improvement=57 percent; light touch=62 percent; foot=SO
percent. No significant difference was found when comparing
the Swedish and light touch massage (95 percent confidence
interval (CI) -0.11, 0.13; p=0.12). Overall, the data is promising regarding improvement in the symptoms of cancer patients receiving massage therapy. If a pharmacist chooses to
recommend massage therapy to a patient, then it is best to
recommend that the patient visit a massage therapist who has
been trained to work with cancer patients. There are various
training and certification programs available for massage therapists seeking to offer specialized care to cancer patients.10

Table 2. Improvements in Symptom Scores after
Massage Therapy,9

Symptom

Improvement

Overall

52.0%

Pain

47.8%

Fatigue

42.9%

Anxiety

59.9%

Nausea

51.4%

Depression

48.9%

Other

48.3%

A systematic review of massage for symptom relief in cancer
patients based on 10 trials came to the conclusion that the
results from the wide variety of studies included in the review on massage therapy were inconclusive as a whole.10
There were improvements in nausea and pain after massage
therapy. However, the improvements in psychological symptoms had mixed results with most of the trials concluding
that anxiety was improved but without a firm conclusion
regarding other psychological benefits of massage therapy.
Overall, the trials completed on massage therapy have
methodological limitations. Larger sample sizes, better randomization and longer follow-up times in order to determine
long-term effects of massage are needed in the future for
stronger results.
Mindfulness-based stress reduction (MBSR) is another nonpharmacologic treatment that has shown an association with
improving symptom presentation in cancer patients.11
Psychological and self-management skills for coping are
important components for cancer survivors. Mindfulness
specifically involves being aware of and attentive to one's
surroundings. These skills can be taught through an eightweek program during which patients learn to cope with
stress by being more aware of the present moment through
meditation and relaxation. A randomized, controlled trial of
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MBSR was carried out in 229 women with stage 0 to stage m
breast cancer by Hoffman et al. The investigators found that
intervention with MBSR was associated with decreases in
fear of recurrence, depression, anxiety and pain. Symptoms
were measured at baseline (Tl; weeks -2 to 0), weeks 8 to 12
(T2), and weeks 12 to 14 (T3). The average age of participants in the study was 49 years, and 214 women completed
the trial. The primary outcome measured was mood, assessed using the Profile of Mood State (POMS). An improvement in mood is represented by lower scores. The mean
score from the POMS at T3 for total mood disturbance was
29.83 for the experimental group versus the mean score of
45.47 for the control group. The mean adjusted differences at
Tl and 95 percent CI at T2 and T3 showed that the mood
state scores in the experimental group were significantly
lower. Thus, this study concluded that MBSR could be included in supportive care for breast cancer patients to help alleviate symptoms related to mood.
A study by Rahmani et al. also showed that MBSR can lead to
reduction in fatigue severity in cancer patients. 12 The Fatigue
Severity Scale was used to assess the fatigue severity of
chronic diseases including various forms of cancer. The patients in the study ranged in age from 30 to 55 years. In the
control group, the fatigue score was 76.85±5. 721 pretest and
71.29±12.938 posttest with a higher score indicating a higher level of fatigue. The score significantly improved for those
with an MBSR intervention from 77.77±4.737 pretest to
37.96±8.810 posttest. Based on these results, MBSR shows
potential as a useful method to decrease fatigue severity in
cancer patients. A pharmacist can recommend a patient to
enroll in an MBSR program which typically lasts for eight
weeks and is taught by psychologists or other instructors
who have been specially trained in MBSR through professional coursework. In a typical MBSR program, skills for
managing stress and how to become aware of the present
time are taught through various methods including meditation, relaxation and yoga. Specifically, these exercises help
cancer patients learn to pay attention to and accept what is
happening to them in the present time without judgment.
There are a variety of other nonpharmacologic options currently being studied that may prove to be beneficial for cancer patients.n Options that involve mental components are
behavioral interventions such as MBSR, hypnosis and music
therapy. The goal of hypnosis is achieving an extremely focused state of mind that can be then used to modify how a
patient perceives sensations. Music therapy and engaging in
prayer have shown to be useful in calming patients with pain
and in training them to better manage their pain. Educational
interventions through videos and specially trained chronic
pain coaches who teach patients about their pain may also
prove beneficial in aiding patients to better understand their
pain. More research on use of these methods in cancer patients has yet to be completed.
Some aspects of Traditional Chinese Medicine (TCM) have
also seen a resurgence of use in cancer patients. 1 3 While not
all TCM is nonpharmacologic, this text focuses on the non-
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pharmacologic components. It is thought that good health is
achieved through a balance between an individual and their
environment. lllness is thought to occur when the flow of qi,
which is an energy force, is inappropriate or blocked. The
balance must be restored with regard to all of the flow patterns. Acupuncture is one form of TCM that is being studied
in cancer patients. There is the belief that imbalances of qi
have physical manifestations, such as joint pain, and that
imbalance can be corrected by inserting small-gauge needles
to help release pressure and restore proper flow. There is
some limited evidence thus far for the use of acupuncture in
cancer patients with postprocedural pain. Additionally, acupuncture is currently being studied to treat patients who
have xerostomia caused by radiation and in patients with
edema in the lower extremities following lymph node dissection. Qigong is another form of TCM and involves altering
energy through slow movements, breathing techniques and
meditation. Similar to acupuncture, the goal is to restore the
flow of qi. The use of Qigong is rare in studies with cancer
patients, but it is thought that it could reduce pain and relieve anxiety.
A review was completed on the current evidence provided
by 2,385 randomized, controlled trials and 579 nonrandomized, controlled studies for TCM in cancer care with 72 percent of the studies using TCM along with standard cancer
treatment (chemotherapy, Western medicine, surgery and
radiotherapy).14 The types ofTCM used in the studies included acupuncture, music therapy and Qigong. Also, it is worth
noting that herbal products, which fall under complementary
and alternative medicine rather than nonpharmacologic
treatment, were also included in many of the studies analyzed. Once again, the results were inconclusive on whether
TCM is beneficial. The sample sizes of many of the studies
available were inadequate, and several of the studies did not
provide adequate reporting of criteria for cancer diagnosis
and patient selection. More standardization is necessary in
future trials as well as a longer follow-up period to assess
long-term benefits. Common benefits such as improved pain
management and decreased depression symptoms were reported across the majority of the studies. This suggests that
TCM does have the potential to be used as nonpharmacologic
treatment, but, as stated previously, more research is necessary. The review suggests that future studies need to include
data on survival times, extent of relapse and metastasis, and
details on effects related to quality of life.
Nonpharmacologic care also includes options that are more
physically oriented. 1 3 Rehabilitative treatments have the potential to improve strength, pain and neuromuscular control
in cancer patients. Transcutaneous electrical stimulation
(TENS) provides low electrical shocks or signals to painful
areas on the body. Studies on nonmalignant pain have shown
that rehabilitative treatment and TENS may show beneficial
results after one to three months. However, studies specifically with cancer patients must be done before pharmacists
can provide appropriate recommendations. Table 3 shows a
comprehensive list of the nonpharmacologic interventions
mentioned in this article.
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Table 3. Summary of Nonpharmacologic lnterventions.9-14
Procedure

Massage Therapy

Mindfulness-Based
Stress Reduction
(MBSR)

Manipulation of soft tissue
areas of the body

Eight-week long program
taught by psychologists or
other trained instructors
during which patients
learn to cope with stress
via meditation and
relaxation

Benefit

Quality of Evidence

More effective in managing
anxiety, fatigue and well-being

NCCN recommends inclusion
of massage therapy in treatment guidelines for refractory
cancer pain

-40% decrease in pain and
anxiety
Decreases in fear of recurrence,
depression, anxiety, physical
functioning, energy and pain

Associated with improved
symptom presentation and
exhibits great potential for use
in supportive care

Reduction in fatigue severity

Behavioral intervention
aimed at achieving an extremely focused state of
mind

Modifies how patients react to
pain

Further studies needed

Music Therapy

Behavioral intervention

Calming effect by training
patients to improve
management of pain

Further studies needed

Prayer

Behavioral intervention

Calming effect by training
patients to improve
management of pain

Further studies needed

Pain Education

Educational intervention
through use of videos
and trained chronic pain
coaches

Help patients better
understand their pain

Further studies needed

Traditional Chinese
Medicine (TCM)
·Acupuncture

Insertion of small-gauge
needles to help release
pressure and restore qi
(life energy force)

Increased analgesia after 3
weekly acupuncture appointments in -50% of patients

Limited evidence available

Traditional Chinese
Medicine (TCM)
-Qigong

Altering energy through
slow movements,
breathing techniques and
meditation to restore qi
(life energy force)

May reduce pain and relieve
anxiety

Limited evidence available

Physically oriented
treatment aimed at
improving strength, pain
and neuromuscular control

May have beneficial results
after 1-3 months of use

Further studies needed

Low electrical shocks or
signals applied to painful
body areas

May have beneficial results
after 1-3 months of use

Further studies needed

Hypnosis

Rehabilitative
Treatment

Transcutaneous
Electrical Stimulation
(TENS)
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Role of the Pharmacist
Pharmacists play an integral role in the management of palliative care. The distinguishing factor of palliative care is the
pharmacist's focus on symptomatic relief, whether it is relief
from nausea, pain, fatigue, vomiting, constipation, insomnia
or dyspnea.1s,16 In addition to pharmacologic monitoring,
pharmacists have a role in recommending and implementing
various nonpharmacologic options. The current health care
culture offers patients and providers multiple options for
providing palliative care in cancer and cancer therapy. There
is also an increasing number of validated nonpharmacologic
options. Thus, health care providers have a responsibility to
remain up-to-date on the established guidelines for palliative
care, but should not ignore other modes of care patients may
use. While communicating with patients regarding possible
options it is important to assess patient willingness and compliance with recommended nonpharmacologic options as
there are options available that are less conventional.17
Treatment regimens vary from patient to patient; however,
optimal treatment involves concurrent pharmacologic and
nonpharmacologic treatments. The most efficient strategy to
ensure the best health outcomes in cancer patients, is the
utilization of a multidisciplinary team. Pharmacists are accountable not only for providing needed knowledge and
skills regarding medication use but also can be helpful in ensuring collaboration with certified professionals trained specifically for the symptomatic treatment of cancer patients.
The list of responsibilities is not exhaustive as pharmacists
are evolving into more of a provider role across multiple
practice settings. Provider status would allow pharmacists to
directly monitor and adjust drug therapy based on lab tests
ordered by the pharmacist and be reimbursed for such services. A need exists to expand the accessibility of palliative
care to community settings in order to better control symptomatic care. The community setting requires enhanced communication between community pharmacists and palliative
care pharmacists in order to provide optimal collaborative
care for the patient. Pharmacists in the community can help
educate patients on options available to them and where to
go to receive appropriate, safe and effective care. As easily
accessible and highly trusted health care professionals,
pharmacists have a duty to know about both appropriate
pharmacologic palliative care and nonpharmacologic alternatives to recommend to patients and providers .
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Assessment Questions
1.

The National Comprehensive Cancer Network (NCCN)
goals for palliative care aim to "__,
and
suffering."
A. detect, prevent and reduce
B. anticipate, eliminate and reduce
C. anticipate, prevent and modify
D. anticipate, prevent and reduce

7.

Inclusion of which type of nonpharmacologic intervention does the NCCN recommend for refractory cancer
pain?
A. Transcutaneous Electrical Stimulation (TENS)
B. Massage therapy
C. Pain education
D. Traditional Chinese Medicine (TCM)

2.

What patient characteristic should be determined in order to provide the best overall approach for management of palliative care in anticancer therapy?
A. Stage of cancer progression
B. Estimated life expectancy
C. Level of pain experienced by the patient
D. Number of medications the patient is taking

8.

Mindfulness-based stress reduction involves enrolling
the patient in a program taught by a
that lasts

What is the primary difference in pain management for
patients with shorter life expectancies?
A. Patients with shorter life expectancies require a
more aggressive approach in titrating medications.
B. Decreasing doses for management of blood
pressure, respiratory rate or consciousness is
necessary for patients with a shorter life expectancy.
C. Dose reduction of opioid medication should occur in patients with a shorter life expectancy.
D. Patients with a shorter life expectancy require
rehydration therapy.

9.

3.

4.

What is a unique aspect to palliative care providers?
A. Helping the patient find an appropriate treatment regimen that is cost-effective.
B. Compounding specialty medications for patients
experiencing severe symptoms.
C. Reassuring the patient that following recommendations will halt disease progression.
D. Preparing the patient psychologically for disease
progression and treatment.

5.

Which of the following should be recommended if firstline treatment for constipation fails?
A. Sennosides
B. Polyethylene glycol
C. Bisacodyl
D. Docusate

6.

Recogni1ing which of the following inducible factors is
imperative to improving patient outcomes related to
cachexia?
A. Dysgeusia
B. Hypogonadism
C. Thyroid dysfunction
D. Oral or pharyngeal candidiasis infection
Summer 2016 Volume
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A.

B.
C.
D.

psychologist, 4 weeks
pharmacist, 8 weeks
pharmacist, 4 weeks
psychologist, 8 weeks

Studies on nonmalignant pain have shown that rehabilitative treatment and transcutaneous electrical stimulation (TENS) may have beneficial results after __.
A. 8weeks
B. 6 months
C. 1-3 months
D. 6-8 weeks

10. What is the main focus of the role of pharmacists in palliative care?
A. Symptom relief
8. Compounding nonstandard dosage forms
C. Ensuring adherence to legal regulations related
to drug containment and disposal
D. Monitoring therapy and adjusting doses based
on renal and hepatic status
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